Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | MMP2 |
| Gene Name: | MMP2 |
| Protein Full Name: | 72 kDa type IV collagenase |
| Alias: | 72 kDa gelatinase; 72 kDa type IV collagenase; CLG4; CLG4A; Collagenase type IV-A; EC 3.4.24.24; Gelatinase A; Gelatinase A gelatinase type IV collagenase; Gelatinase A MMP-2; Matrix metallopeptidase 2; MMP-2; MMP-II; MONA; TBE-1 |
| Mass (Da): | 73882 |
| Number AA: | 660 |
| UniProt ID: | P08253 |
| Locus ID: | 4313 |
| COSMIC ID: | MMP2 |
| Gene location on chromosome: | 16q13-q21 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20320 |
| Percent of cancer specimens with mutations: | 0.93 |
| Normal role description: | Protease - matrix metalloproteinase - secreted. Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumour invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumour properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin. Ligand for integrinv/beta3 on the surface of blood vessels. MMP2 may promote tumour growth and metastasis through degradation of the ECM. |
| Commentary on involvement of protein in cancer: | Less than 3% muations in CNS, Kidney and lung cancer. |